The week in numbers * $10.6B all-cash: GSK to acquire Nuvalent (Nasdaq: NUVL), a clinical-stage precision-oncology company, at $124.00 per share (about a 40% premium, roughly $9.4B net of Nuvalent's cash) via a tender offer for all Class A and Class B shares.

A no-royalty threshold is a contractually defined level of net sales, time, or performance below which the buyer of a royalty receives nothing. The mechanism is uncontroversial in concept and notoriously consequential in practice. It moves cash flow timing, reshapes IRR distributions, alters accounting recognition, complicates true-sale opinions,

Cogent Biosciences, Inc. (Nasdaq: COGT) is a Waltham and Boulder based biotechnology company developing precision therapies for genetically defined diseases. Its single clinical-stage product, bezuclastinib, is a selective tyrosine kinase inhibitor of the KIT D816V mutation and other KIT exon 17 mutations, and is the engine behind three near-

What is High-Tech Gründerfonds? High-Tech Gründerfonds (HTGF) is Germany's largest and most active seed-stage venture investor. It is a public-private partnership, founded in 2005 in Bonn to close the early-stage funding gap that once left many German university and research spin-outs without

A mechanics-and-gap analysis of royalties in digital health and prescription digital therapeutics as of 2026.

Why animal-health royalties are structured the way they are: FDA-CVM regulatory triggers, species fragmentation, the cash-pay market, the option-to-acquire lifecycle that keeps eliminating royalties, and the deleveraging monetizations, with the numbers and the deal anatomy.

A generative model does not know what it does not know. When it proposes a molecule, a binding pose, or a mechanism, the practical question, for anyone reading its output or underwriting the platform that produced it, is whether the answer is real or a confident fiction.

The week in numbers Disclosed cash and committed capital first. The milestone-inclusive "up to" ceilings are noted second, not led with: where an upfront or a committed amount is disclosed, that is the number to anchor on. * $1.55B upfront cash: Servier to Edgewise for the muscular

A royalty stream is only as good as the documents that prove it. The data room is where a buyer decides whether the cashflow it is being shown is real, durable, transferable, and unencumbered. Get the room right and a deal closes in weeks. Get it wrong and the buyer